a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc)

April 2013

You'll hear more about a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc).

New evidence suggests about one more case of acute pancreatitis for every 50 diabetes patients using these drugs for up to 2 years.

These incretin mimetics might cause inflammation that could lead to acute pancreatitis...and possibly pancreatic cancer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Antihypertensives BIG changes in how hypertension and dyslipidemia are managed
Headache overuse of headache meds for just a few months can actually make their headaches worse
Diabetes a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc)
Pediatrics limiting antibiotics in kids with acute otitis media (AOM)
Pediatrics A new "black box" warning will alert prescribers NOT to use codeine in children after a tonsillectomy or adenoidectomy
Cardiology ACE inhibitors help reduce SYMPTOMS of peripheral artery disease (PAD)
Anticoagulants using the new oral anticoagulants (Pradaxa, Xarelto, Eliquis) for "off-label" uses
NSAIDs kidney risks of NSAIDs
Calcium more negative press about calcium supplements
Constipation Many myths about constipation lead to inappropriate treatment
Cardiology confusion about metoprolol prescriptions